Sana Biotechnology (SANA) Stock Price, News & Analysis

Company Overview

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials.

Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic.

Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.

Key Stats

• Today's Range: $3.61 to $4.02
• 50-Day Range: $2.68 to $4.01
• 52-Week Range: $2.61 to $6.55
• Volume: 5.25 million shs
• Average Volume: 3.92 million shs
• Market Capitalization: $1.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Moderate Buy

Sana Biotechnology Stock Analysis - MarketRank™

Sana Biotechnology scored higher than 46% of companies evaluated by MarketBeat, and ranked 499th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Sana Biotechnology has a consensus price target of $9.50, representing about 136.9% upside from its current price of $4.01.

Amount of Analyst Coverage

Sana Biotechnology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sana Biotechnology are expected to grow in the coming year, from ($0.59) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sana Biotechnology is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sana Biotechnology is -4.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sana Biotechnology has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.59% of the float of Sana Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Sana Biotechnology has a short interest ratio ("days to cover") of 11.06, which indicates bearish sentiment.

Change versus previous month

Short interest in Sana Biotechnology has recently increased by 3.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sana Biotechnology does not currently pay a dividend.

Dividend Growth

Sana Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.25

News Sentiment

Sana Biotechnology has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sana Biotechnology this week, compared to 3 articles on an average week.

Search Interest

Only 6 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

MarketBeat Follows

9 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.40% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 7/04/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SANA
• CIK: 1770121
• Web: sana.com
• Phone: 206-701-7914
• Fax: N/A
• Employees: 380
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Sana Biotechnology: $9.50
• High Price Target: $16.00
• Low Price Target: $7.00
• Potential Upside/Downside: +136.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$244.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -108.01%
• Return on Assets: -40.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.29
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.60 per share
• Price / Book: 6.68

Miscellaneous

• Outstanding Shares: 278,290,000
• Free Float: 207,606,000
• Market Cap: $1.12 billion
• Optionable: Optionable
• Beta: 2.13